Scott Richter

Gedeon Richter: Cariprazine shows effectiveness in the treatment for dual disorder

Retrieved on: 
Monday, April 15, 2024
Crave, Disorder, Congress, European Psychiatric Association, Gedeon Richter, Poster, DSM-IV codes, Cariprazine, Science, Patient, Scott Richter, Observational study, Medical diagnosis, Caregiver, Anxiety, Mood, Pharmaceutical industry

The scientific posters proved that cariprazine might be an appropriate treatment not only for early and late-stage schizophrenia, but also for the difficult-to-treat dual disorder (schizophrenia and comorbid substance use disorder).

Key Points: 
  • The scientific posters proved that cariprazine might be an appropriate treatment not only for early and late-stage schizophrenia, but also for the difficult-to-treat dual disorder (schizophrenia and comorbid substance use disorder).
  • Furthermore, a new transdiagnostic tool for quantifying, and visualizing symptom severity and functional disability of patients with different psychiatric conditions was presented.
  • A special Gedeon Richter publication, the "Candid Book" was also introduced by the authors, which contains useful, everyday suggestions for the caregivers of patients.
  • The final poster was providing information on the potential of cariprazine in dual disorder, the co-occurrence of a major psychiatric disorder and comorbid substance use disorder.

EQS-News: Gedeon Richter becomes strategic investor of Formycon via equity investment

Retrieved on: 
Tuesday, January 30, 2024
XETRA, Research, FWB, CFO, Partnership, Scott Richter, Supervisory board, Gedeon Richter, EUR, Security (finance)

Press Release // January 29, 2024

Key Points: 
  • Press Release // January 29, 2024
    Transaction opens up possibility of jointly leveraging long-term strategic opportunities across development, manufacturing and commercial value streams
    Munich, Germany/Budapest, Hungary – Formycon AG (FWB: FYB) (“Formycon”) today announced that Hungary based specialty pharmaceutical company Gedeon Richter Plc.
  • (“Gedeon Richter“) becomes strategic investor via cash capital increase from authorized capital in the amount of 9.08% of Formycon’s share capital.
  • Both companies are convinced of the huge potential of biosimilars and share the strategic proximity as well as the respective expertise in their fields of activity.
  • Based on the resolutions of Formycon’s Management Board and Supervisory Board, Gedeon Richter subscribed a cash capital increase of 9.08% in a private placement.

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Retrieved on: 
Thursday, November 2, 2023
Type, Gedeon Richter, Health care, CHMP, Gesellschaft mit beschränkter Haftung, History, Scott Richter, Committee, Committee on Herbal Medicinal Products, European Medicines Agency, Health, Uterine fibroid, Women's Healthcare in the 20th Century United States, SMPS, European, EMA, Committee for Medicinal Products for Human Use, Woman, SMPA, Endometriosis, Dietary supplement, Pharmaceutical industry, EU

('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland, GmbH ('SMPS') today announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Key Points: 
  • ('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland, GmbH ('SMPS') today announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
  • RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.
  • "We are delighted that this approval has opened the way to offer a viable symptomatic treatment option for many women living with endometriosis" - said Dr. Peter Turek, Global Head of Women's Health at Gedeon Richter.
  • "Approximately 14 million women in the European Union are living with endometriosis, a chronic condition whose painful symptoms can impact a woman's ability to engage in certain daily activities.

Gedeon Richter: an effective treatment for female schizophrenia patients

Retrieved on: 
Wednesday, October 18, 2023
Cariprazine, Hallucination, Scott Richter, Physician, Asociality, Observational study, Alogia, Patient, ECNP, Gideon, Delusion, Anhedonia, European College of Neuropsychopharmacology, Risperidone, Woman, Pharmaceutical industry, Schizophrenia

Cariprazine was found to be effective in women with schizophrenia in a real-life setting with around 70% of the physicians being satisfied with the results.

Key Points: 
  • Cariprazine was found to be effective in women with schizophrenia in a real-life setting with around 70% of the physicians being satisfied with the results.
  • Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting about 1% of the population.
  • Although antipsychotics are effective in the treatment of positive symptoms, the management of negative, cognitive, and affective symptoms often remains challenging.
  • Treatment with risperidone is still one of the most used standards when it comes to schizophrenia.

Gedeon Richter: A new hope for treatment-resistant schizophrenia?

Retrieved on: 
Thursday, October 5, 2023
Scott Richter, Congress, Safety, Cariprazine, Clozapine, World Psychiatric Association, TRS, Gedeon Richter (company), Gedeon Richter, Patient, Pharmaceutical industry, Schizophrenia, Psychiatry

Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.

Key Points: 
  • Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.
  • Although antipsychotics are effective in the treatment of positive symptoms, the management of negative, cognitive, and affective symptoms often remains challenging.
  • Cariprazine is a 3rd generation antipsychotic medication with a unique receptor profile and proven efficacy in persistent negative symptoms.
  • At the Gedeon Richter and Recordati supported Meet-the-Expert session, Professor Christoph U. Correll talked about the activating-sedating effects of antipsychotics with special focus on cariprazine.

Global Biosimilars Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 18, 2023
Biotechnology, Pharmaceutical, Health, Amgen, Asthma, CMS, Etanercept, Fresenius (company), Prevalence, Diabetes, Trastuzumab, Ustekinumab, Medicare, Inflation, Chronic condition, Patient, Analysis, Conditional sentence, Biosimilar, Rheumatoid arthritis, Centers for Medicare & Medicaid Services, Research, EMA, Tocilizumab, Ophthalmology, Fresenius, Knowledge, Growth, FDA, Celltrion, Legislation, Welfare, Arthritis, COVID-19, Cancer, Medicare Part D, Competitive landscape, Novartis, AbbVie, Inflation Reduction Act of 2022, Teva Pharmaceuticals, Biogen, Rituximab, Education, Eating, IRA, Sale, Movement, Scott Richter, Local Investing Opportunity Network, Physician, Fine chemical, Generic drug, Vaccine, Pharmaceutical industry, Natalizumab, Adalimumab, Ranibizumab

The "Global Biosimilars Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Biosimilars Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update" report has been added to ResearchAndMarkets.com's offering.
  • In these volatile market conditions, the biosimilars market is still expanding dramatically, and the outlook is as promising.
  • It provides a detailed analysis of biosimilar market dynamics, covering clinical trials, patent data, financial deals, and company profiling details.
  • In addition, this report provides analyst commentary on key trends, drivers, strategies, innovations, and regulations in the field of biosimilars.

Gedeon Richter: Cariprazine demonstrates broad-spectrum antidepressant effects across different patient populations

Retrieved on: 
Wednesday, March 29, 2023
Depression, Depression (mood), Observational study, Hospital, Suicide, Clinical trial, Quality of life, EPA, Plasma, Scott Richter, DSM-IV codes, Patient, Risk, Grammatical mood, Diagnosis, Poster, Knowledge, European Psychiatric Association, Cariprazine, Bipolar disorder, Total, Pharmaceutical industry, TRR, Schizophrenia

Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.

Key Points: 
  • Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.
  • Although antipsychotics are effective in the treatment of positive symptoms, the management of negative, cognitive, and affective symptoms often remains challenging.
  • Another poster highlighted the increasing need for gathering real-world data in order to understand how the drug works in heterogeneous patient populations, therefore complementing the knowledge gained from clinical trials.
  • The 3rd poster provided details on the examination of the therapeutic reference range (TRR) for cariprazine 1.5 mg/day to 6 mg/day in schizophrenia studies.

Best Practices in Safety Signal Analytics -- Managing Today and Preparing for Tomorrow, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, March 28, 2023
Real-World Evidence, Product management, Scott Richter, Drug Safety, FDA, Real world data, Safety, Television, Pharmacovigilance

TORONTO, March 28, 2023 /PRNewswire-PRWeb/ -- With safety signal case volumes increasing 30 to 50 percent annually, how are pharmacovigilance teams managing with today's constrained budgets, and what can real-world data and advanced cognitive computing do for tomorrow?

Key Points: 
  • In this free webinar, learn from top pharmacovigilance professionals and engage in this invaluable conversation on the challenges, successes, and future innovations relevant to safety signal analytics.
  • Attendees will learn how real-world data and advanced cognitive computing are creating innovations now and in the future for safety signal analytics.
  • This webinar will feature pharmacovigilance industry experts from across life sciences as they discuss:
    What trends and challenges are safety signal teams facing today and how are they currently managing these issues?
  • With 70% of biopharma seeing a maturity gap in safety signal analytics processing, what feasible steps will be taken toward improving safety signal analytics this year?

Breaking Down Barriers in Support of Patients with Rare Diseases, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, February 1, 2023
MBA, Gene therapy, Scottish Informatics and Computer Science Alliance, RN, RAPT, Patient, Clinical trial, Scott Richter, Research, Labcorp Drug Development, Labcorp, Rare, Disease, Growth, MPH, Critical Path Institute, CCRC, Doctor of Philosophy, Pharmaceutical industry, Nursing, Science, MD

TORONTO, Feb. 1, 2023 /PRNewswire-PRWeb/ -- There are over 7,000 rare diseases, and one in 10 individuals worldwide have a rare disease. Over 675 diseases have some research and development targeting supportive care, treatment or a cure for these patients, with approximately only 5% of indications having a treatment available. There is tremendous opportunity and an even larger patient need.

Key Points: 
  • The featured speakers will discuss early scientific networking in a rare disease study by partnering with patient advocacy groups.
  • The speakers will share insights about engagement and retention of patients in clinical trials, expanded access programs and patient registries.
  • The speakers will also discuss Labcorp's strategy to overcome critical barriers with innovative solutions to efficiently conduct rare disease studies.
  • Ways to successfully collaborate with patients, families and advocacy groups
    Register to learn about breaking down barriers in support of patients with rare diseases.

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022

Retrieved on: 
Thursday, January 26, 2023
Research, Prostate cancer, Food, Gonadotropin-releasing hormone, USPI, Scott Richter, Endometriosis, Hart–Scott–Rodino Antitrust Improvements Act, History, Sale, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, SG, Roivant Sciences, SPIRIT, ORGOVYX, New Drug Application, EMA, Woman, RWS, Shanda, United Kingdom, Type 2, TRX, Richter, Pain, Safety, PDUFA, R, NYSE, Type, Risk, European Medicines Agency, Calendar, Patient, Growth, Uterine fibroid, German–Soviet Commercial Agreement (1940), Leuprorelin, Video game, Fine chemical, Credit, Security (finance), Pharmaceutical industry, Health insurance, Medical imaging, Airline, Takeda, Accord, Pfizer

Third fiscal quarter 2022 net product revenues for ORGOVYX in the U.S. were $48.7 million, reflecting 12% sequential growth compared to the second fiscal quarter 2022.

Key Points: 
  • Third fiscal quarter 2022 net product revenues for ORGOVYX in the U.S. were $48.7 million, reflecting 12% sequential growth compared to the second fiscal quarter 2022.
  • Approximately 4,000 new patients started treatment with ORGOVYX in the third fiscal quarter of 2022, reaching approximately 26,000 cumulative patients since launch.
  • In December 2022, Myovant completed a New Drug Submission to Health Canada seeking marketing approval for ORGOVYX for advanced prostate cancer.
  • Third fiscal quarter 2022 net product revenues for MYFEMBREE in the U.S. were $10.5 million, reflecting 64% sequential growth compared to second fiscal quarter 2022.